& The Motley Fool & Monument Trader’s Alliance (MTA)
Good day, 360! Here are some of our top movers today. And…. friends don’t let friends trade ALONE!
Monday’s Lineup (EST):
12pm – Hop over to Nate Bear to trade his Pick of the MONTH(*affiliate for MTA)
Be the best prepared (and least lonely!) trader on the Street!
FOCUS LIST🔎
MRM – Up over 40% in the pre-market after receiving orders for over 25,000 MOTHER bracelet units
GXAI – 2nd day play, up over 50% in pre after closing Friday up over 80%
IPHA – Up over 35% in pre after announcing Lacutamab improved health-related quality of life data at ASH 2024 from TELLOMAK Phase 2 study in patients with Cutaneous T Cell Lymphoma
*sponsored by Cizzle Bio
You can be part of a life-saving mission.
Invest in Cizzle Biotech’s groundbreaking early-detection blood test, designed to catch lung cancer before symptoms appear. With over 95% accuracy and strong backing from partners like Bio-Techne and Moffitt Cancer Center, our innovation has the potential to save millions of lives and transform healthcare. Join us in making early detection accessible—and take part in reshaping the future of medical diagnostics.
Read the Offering information carefully before investing. It contains details of the issuer’s business, risks, charges, expenses, and other information, which should be considered before investing. Obtain a Form C and Offering Memorandum at invest.cizzlebio.com
HOTLIST🔥
MEDIROM Healthcare Technologies Inc. (MRM) together with its subsidiaries, provides holistic health services in Japan. It operates in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty.
In the after-hours on Friday, the company announced that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, including orders from Japanese companies such as NFES Technologies Inc.
Kouji Eguchi, CEO, MEDIROM, stated:
‘Our long-term mission is for the Mother Bracelet to be revolutionary in the Healthcare Technology and Wellness industries. The 25,000 unit MOTHER Bracelet orders surpasses the amount we’ve received and fulfilled to date and shows the continued momentum of our market penetration.’
Shares of MRM traded up over 40% in the pre-market in reaction to the news.
The $4.15 area acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $4.80, $5, $6, $6.40, $7.70 and then the pre-market high at $8.48.
Below $4.15, targets to the downside are $3.40 and then a gap fill at $3.05.
GXAI – 2nd day play, up over 50% in pre after closing Friday up over 80%
Gaxos.ai Inc. (GXAI) engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming.
On Friday, the company unveiled its visual editor for Godot gaming engine for their artificial intelligence solution for game developers and publishers, Gaxos Labs. The Godot visual editor introduces a user-friendly interface that simplifies the process of embedding AI-driven features directly into game projects.
Shares of GXAI traded up over 80% on the close Friday and have continued another 50% higher this morning in the pre-market in reaction to the news.
The $3.60 area was resistance in the after-hours and so far has acted as support in the pre-market.
Above it, targets to the upside are $4, $4.50, $4.70 and then the pre-market high at $4.90/
Below $3.60, targets to the downside are $3, $2.50, $2.25 and then $2.
*sponsored by The Motley Fool
Smart Money, Smart Machines
Dubbed “the rocket fuel of AI” by Wired, this innovation is causing a stir on Wall Street. With projections hitting $80 trillion – that’s 41 Amazons – the potential is huge. But here’s the deal: sharp investors who are ahead of the game have the opportunity to invest in a technology poised for domination. Thanks to The Motley Fool, you can access the full story in this exclusive report.
IPHA – Up over 35% in pre after announcing Lacutamab improved health-related quality of life data at ASH 2024 from TELLOMAK Phase 2 study in patients with Cutaneous T Cell Lymphoma
Innate Pharma S.A. (IPHA) is a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
In the pre-market this morning, the company announcednew data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study.
Highlights include:
Patients with relapsed or refractory CTCL face limited treatment options and often report lower health-related quality of life, particularly those in advanced stages.
TELLOMAK’s findings reveal promising signs that Lacutamab may help alleviate some of the most distressing symptoms of this disease early on treatment.
The TELLOMAK trial enrolled 163 patients with advanced CTCL, including 56 with SS and 107 with MF. The study’s quality of life measures included the Visual Analogue Scale (VAS) for itch intensity and the Skindex-29 score, a validated tool for assessing the impact of skin conditions on patient quality of life.
Shares of IPHA traded up over 35% in the pre-market in reaction to the news.
The $1.80 area acted as support in the pre-marker and will be an important level to watch.
Above it, targets to the upside are $2, $2.10, $2.50 and then the pre-market high at $2.57.
Below $1.80, targets to the downside are $1.70 and then a gap fill at $1.47.
MARKET NEWS 📰
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
